Apotex Inc — licence 100375, currently licensed, last inspection rating C (2026-04-21).
No Canadian shortage report is currently matched to this DIN.
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02564831 | APO-LEVOMILNACIPRAN | APOTEX INC | Capsule (Extended-Release) | LEVOMILNACIPRAN (LEVOMILNACIPRAN HYDROCHLORIDE) 20 MG | Approved |
| 02564866 | APO-LEVOMILNACIPRAN | APOTEX INC | Capsule (Extended-Release) | LEVOMILNACIPRAN (LEVOMILNACIPRAN HYDROCHLORIDE) 80 MG | Approved |
| 02564874 | APO-LEVOMILNACIPRAN | APOTEX INC | Capsule (Extended-Release) | LEVOMILNACIPRAN (LEVOMILNACIPRAN HYDROCHLORIDE) 120 MG | Approved |
| 02440970 | FETZIMA | ABBVIE CORPORATION | Capsule (Extended-Release) | LEVOMILNACIPRAN (LEVOMILNACIPRAN HYDROCHLORIDE) 20 MG | Marketed |
| 02441004 | FETZIMA | ABBVIE CORPORATION | Capsule (Extended-Release) | LEVOMILNACIPRAN (LEVOMILNACIPRAN HYDROCHLORIDE) 120 MG | Marketed |
| 02440989 | FETZIMA | ABBVIE CORPORATION | Capsule (Extended-Release) | LEVOMILNACIPRAN (LEVOMILNACIPRAN HYDROCHLORIDE) 40 MG | Marketed |
| 02440997 | FETZIMA | ABBVIE CORPORATION | Capsule (Extended-Release) | LEVOMILNACIPRAN (LEVOMILNACIPRAN HYDROCHLORIDE) 80 MG | Marketed |